PB-NK cell product
CYTOTOXICITY
PB-NK cell expansion to the target dose was reached in all 10 patients with a mean NK cell purity of 94.8% (91.3– 97.5%), and we were able to evaluate the cytotoxicity of these cells in some patients (5/10). In line with our preclinical data, the NK cells were highly functional with CD107a degranulation IFN-γ production in response to the K562 cell line (Fig. 
Expanded PB-NK cells reveal an active phenotype before infusion. 